Evidence map›Paper›PMID 30838775›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2019

Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation.

Rita R Alloway, E Steve Woodle, Daniel Abramowicz, Dorry L Segev, Remi Castan, Jillian N Ilsley, Kari Jeschke, Kenneth Troy Somerville, Daniel C Brennan

Open access · bronzeAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Immunosuppressants/Immunomodulators and Malignancy.Journal of clinical medicine · 2025
    Review
  11. Article
  12. Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  13. History of Heart Transplant: Setting the Stage.Methodist DeBakey cardiovascular journal · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Rita R AllowayDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
E Steve WoodleDivision of Transplantation, Department of Surgery, University of Cincinnati, Cincinnati, Ohio.
Daniel AbramowiczDepartment of Nephrology, Universitair Ziekenhuis Antwerpen, and Antwerp University, Edegem, Belgium.
Dorry L SegevDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Remi CastanSanofi, Vitry-sur-Seine, France.
Jillian N IlsleySanofi Genzyme, Cambridge, Massachusetts.
Kari JeschkeSanofi Genzyme, Cambridge, Massachusetts.
Kenneth Troy SomervilleSanofi Genzyme, Cambridge, Massachusetts.
Daniel C BrennanDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sanofi (United States) · USUniversity of Cincinnati · USAntwerp University Hospital · BEJohns Hopkins Medicine · USJohns Hopkins University · USSanofi (France) · FR

Funding

Sanofi Genzyme
6 · The paper itself

Abstract

This report describes the results of 2 international randomized trials (total of 508 kidney transplant recipients). The primary objective was to assess the noninferiority of rabbit anti-thymocyte globulin (rATG, Thymoglobulin

Indexed as

AnimalsAntilymphocyte SerumBasiliximabGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney Failure, ChronicKidney Function TestsKidney TransplantationPrognosisRabbitsRandomized Controlled Trials as TopicReceptors, Interleukin-2Risk FactorsAntilymphocyte SerumBasiliximabImmunosuppressive AgentsReceptors, Interleukin-2autoimmunityclinical research/practiceclinical trialimmunosuppressant - polyclonal preparations: rabbit antithymocyte globulinimmunosuppression/immune modulationimmunosuppressive regimens - inductionkidney (allograft) function/dysfunctionkidney transplantation/nephrology

Identifiers

PMID30838775
PMCPMC6767488
OpenAlexW2921612074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.